Abstract: The present invention provides peptidal fragments of human immunodeficiency virus (HIV) which interact specifically with a particular human leucocyte antigen (HLA) class I molecule to stimulate cytotoxic T lymphocyte immunity.
Type:
Grant
Filed:
July 6, 1992
Date of Patent:
January 2, 1996
Assignee:
United Biomedical, Inc.
Inventors:
Andre J. McMichael, Douglas F. Nixon, Alain R. M. Townsend, Frances M. Gotch
Abstract: Peptides are described which have the amino acid sequence of a fragment of HIV (human immunodeficiency virus) which interacts specifically with a particular human leucocyte antigen (HLA) class I molecule, to stimulate cytotoxic T lymphocyte immunity. Such fragments can be used in a potential vaccine against AIDS (acquired immune deficiency syndrome), and for diagnostic and therapeutic purposes.
Type:
Grant
Filed:
December 31, 1992
Date of Patent:
October 17, 1995
Assignee:
United Biomedical, Inc.
Inventors:
Andrew J. McMichael, Douglas F. Nixon, Alain R. M. Townsend
Abstract: The present invention provides an attenuated, genetically-engineered pseudorabies virus designated S-PRY-155 (ATCC Accession No. VR 2311). A vaccine is provided which comprises an effective immunizing amount of S-PRY-155 and a suitable carrier. A method of immunizing an animal against disease caused by pseudorabies virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine. The present invention also provides a method for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring, wild-type pseudorabies virus.
Abstract: The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.